483 related articles for article (PubMed ID: 24911663)
1. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
[TBL] [Abstract][Full Text] [Related]
2. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
Uesugi M; Hosokawa M; Shinke H; Hashimoto E; Takahashi T; Kawai T; Matsubara K; Ogawa K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Biol Pharm Bull; 2013; 36(11):1814-21. PubMed ID: 24189425
[TBL] [Abstract][Full Text] [Related]
3. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
4. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
Buendia JA; Bramuglia G; Staatz CE
Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
[TBL] [Abstract][Full Text] [Related]
5. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients.
Masuda S; Goto M; Fukatsu S; Uesugi M; Ogura Y; Oike F; Kiuchi T; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2006 Jan; 79(1):90-102. PubMed ID: 16413244
[TBL] [Abstract][Full Text] [Related]
6. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
Wang L; Li N; Wang MX; Lu SC
Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
[TBL] [Abstract][Full Text] [Related]
7. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.
Xue F; Han L; Chen Y; Xi Z; Li Q; Xu N; Xia Y; Streicher K; Zhang J; Xia Q
Pediatr Transplant; 2014 Mar; 18(2):166-76. PubMed ID: 24438215
[TBL] [Abstract][Full Text] [Related]
8. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
[TBL] [Abstract][Full Text] [Related]
14. Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients.
Mizuno S; Nakatani K; Muraki Y; Tanemura A; Azumi Y; Kuriyama N; Ohsawa I; Kishiwada M; Usui M; Sakurai H; Tabata M; Okuda M; Nobori T; Isaji S
Ann Transplant; 2013 Jul; 18():349-57. PubMed ID: 23845965
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients.
Muraki Y; Usui M; Isaji S; Mizuno S; Nakatani K; Yamada T; Iwamoto T; Uemoto S; Nobori T; Okuda M
Ann Transplant; 2011; 16(4):55-62. PubMed ID: 22210422
[TBL] [Abstract][Full Text] [Related]
16. Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patients.
Hosohata K; Uesugi M; Hashi S; Hosokawa M; Inui K; Matsubara K; Ogawa K; Fujimoto Y; Kaido T; Uemoto S; Masuda S
Drug Metab Pharmacokinet; 2014; 29(1):83-9. PubMed ID: 23955548
[TBL] [Abstract][Full Text] [Related]
17. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.
Uesugi M; Masuda S; Katsura T; Oike F; Takada Y; Inui K
Pharmacogenet Genomics; 2006 Feb; 16(2):119-27. PubMed ID: 16424824
[TBL] [Abstract][Full Text] [Related]
18. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
[TBL] [Abstract][Full Text] [Related]
19. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
[TBL] [Abstract][Full Text] [Related]
20. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
Gómez-Bravo MA; Apellaniz-Ruiz M; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Bilbao I; Alamo JM; Millán O; Brunet M; Rodríguez-Antona C
Pharmacogenet Genomics; 2018 Feb; 28(2):41-48. PubMed ID: 29256966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]